Psychological Concomitants of Morquio Syndrome (The MAP Study)
Status: | Completed |
---|---|
Conditions: | Orthopedic, Metabolic |
Therapuetic Areas: | Pharmacology / Toxicology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/30/2013 |
Start Date: | July 2012 |
End Date: | May 2014 |
Contact: | Nadia Ali, Ph.D. |
Email: | Nadia.Ali@emory.edu |
Phone: | 404-778-8613 |
Psychological Concomitants of Morquio Syndrome
Mucopolysaccharidosis IV, also known as MPS IV or Morquio disease, is a rare autosomal
recessive genetic lysosomal storage disorder. Research thus far regarding lysosomal
storage diseases (LSDs) in general, including Morquio, has primarily focused on exploring
the causes of and finding a treatment for the physical aspects of the various diseases.
Less attention has been paid to the psychological or emotional toll of these diseases,
whether they are direct symptoms of the diseases themselves or reactions to living with a
chronic progressive disease.
It is well established in the health psychology literature, however, that the interaction
between our physical health and our psychological health is bidirectional; that is, just as
our physical health affects us emotionally (e.g. chronic pain can contribute to depression),
so can our psychological health affect us physically (e.g. anxiety can contribute to
feelings of chest pain). It is thus critically important to pay attention to the emotional
and psychological symptoms associated with all lysosomal storage diseases, including
Morquio, and expand our treatment standard of care to include mental health treatment, if
necessary.
The first step in understanding and treating psychological conditions in Morquio disease is
determining the natural occurrence of psychological symptoms in this population in
comparison with non-medical populations. As little has been done in this regard, a pilot
study documenting the occurrence rate of psychological issues and overall quality of life in
patients with Morquio is the first item in order and will be the focus of this study.
Approximately 20 patients with Morquio disease will be invited to participate, recruited
through Emory's Lysosomal Storage Disease Center, as well as through attendance at Morquio
support groups and relevant regional, national and/or international meetings. Once
consented, patients will be asked to complete three different self-report questionnaires,
including the Achenbach System of Empirically Based Assessment (ASEBA) Adult Self-Report
(ASR) or Older Adult Self-Report (OASR) questionnaire, the Short Form 36-item Health
Questionnaire (SF-36), and the Brief Pain Inventory (BPI). Group aggregate data only will
be reported; individual questionnaire content and results will be held confidential, except
as in accordance with Georgia law relating to reporting of child or elder abuse, suicidal
and/or homicidal intent. Completion of these questionnaires will complete subjects'
participation in this pilot study.
Inclusion Criteria:
1. Documented clinical diagnosis of MPS IV based on clinical signs and symptoms of MPS
IV and documented reduced fibroblast or leukocyte GALNS enzyme activity or genetic
testing confirming diagnosis of MPS IV.
2. Patient is at least 18 years old.
3. Patient is not currently receiving enzyme replacement therapy for MPS IV.
4. Patient must provide written, informed consent prior to study participation.
Exclusion Criteria:
1. Previous treatment with ERT
2. Previous hematopoietic stem-cell transplant
3. Patient has a clinically significant disease (with the exception of symptoms of
Morquio), including clinically significant immunologic, pulmonary, neurologic, or
renal disease, or other medical condition, serious intercurrent illness, or
extenuating circumstances that, in the opinion of the investigator, would confound
the effects of Morquio upon study variables
We found this trial at
1
site
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials